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Background: Ovarian cancer is one of the most lethal malignancies in women, as it is frequently detected at an
advanced stage, and cancers often become refractory to chemotherapy. Evidence suggests that dysregulation of
pro-apoptotic genes plays a key role in the onset of chemoresistance. The secreted Frizzled-Related Protein (sFRP)
family is pro-apoptotic and also a negative modulator of the Wnt signalling cascade. Studies have demonstrated
that the re-expression of sFRPs, in particular sFRP4, is associated with a better prognosis, and that experimentally
induced expression results in cell death.
Results: In vitro experimental models determined that sFRP4 was differentially expressed in chemosensitive (A2780)
and chemoresistant (A2780 ADR and A2780 Cis) ovarian cell lines, with chemosensitive cells expressing significantly
higher levels of sFRP4. Transfection of the chemoresistant cell lines with sFRP4 significantly increased their
sensitivity to chemotherapy. Conversely, silencing of sFRP4 expression in the chemosensitive cell line resulted in a
corresponding increase in chemoresistance. Comparison of sFRP4 expression in tumour biopsies revealed a positive
trend between sFRP4 expression and tumour grade, with mucinous cyst adenocarcinomas exhibiting significantly
decreased sFRP4 levels compared to mucinous borderline tumours.
Conclusions: This study indicates a role for sFRP4 as a predictive marker of chemosensitivity in ovarian cancer and
suggests that this pathway may be worth exploiting for novel therapies.
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biopsyBackground
Ovarian cancer is the fifth leading cause of cancer deaths
in women, with epithelial ovarian carcinomas being the
most prevalent type diagnosed [1-4]. Chemoresistance, a
common development in ovarian carcinomas, is a major
hurdle that significantly hinders treatment success [5,6].
Recent evidence suggests that the dysregulation of pro-
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reproduction in any medium, provided the ormaintenance of chemoresistance [5,7]. One of such pro-
apoptotic gene families is the Secreted Frizzled-Related
protein (sFRPs) family, an antagonist of the Wnt signal-
ling pathway. sFRPs have a shared homology with
Frizzled receptors and are thought to be able to impede
Wnt-Fz interactions, thereby blocking Wnt activity in
cells. Wnts have been established to play essential roles
during foetal development [1,8-14] as well as maintain-
ing homeostasis in adult tissues [15]. However, aberrant
canonical Wnt signalling has been widely described in
cancer and has been implicated as an important con-
tributor to tumour development [1,8,12]. Several studiestd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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sFRP expression, in particular that of sFRP4, and apop-
tosis in various tissues [16-22]. The over-expression of
sFRPs has been shown to decrease β-catenin levels
within the cells, thus increasing their susceptibility to
pro-apoptotic stimuli [23-25]. While restoration or up-
regulation of sFRP expression in cancer cells was shown
to attenuate their tumourigenic behaviour by inhibiting
Wnt signalling and inducing apoptosis [9,25-31], hyper-
methylated silencing of sFRP genes tended to increase
with tumour progression and invasiveness [29,32,33].
In this study we investigated the effects of over-
expressing or silencing of sFRP4 in ovarian cancer lines
with different chemosensitivity in an in vitro model. We
further examined sFRP4 expression in human ovarian
tumours to assess if its expression could be correlated with
clinico-pathological features consistent with a proposed
role for loss being a contributor to chemoresistance.
Results
Differential expression of sFRP isoforms in ovarian cancer
cell lines
The expression profiles of all 5 isoforms of sFRP were




















































Figure 1 Comparison of quantitated sFRP4 expression across the fou
was compared to IOSE (normal) ovarian cell line. (A) sFRP4 mRNA expressio
lines. Values represent means for each group ± SEM (*p < 0.05; ** p < 0.00sFRP2 was not detected in any of the cell lines (data not
shown), and only sFRP4 was differentially expressed be-
tween the chemosensitive (A2780) and chemoresistant
cancer cell lines (A2780-ADR and A2780-Cis); with
A2780 expressing significantly higher mRNA levels of
sFRP4 in comparison to the A2780-ADR and A2780-Cis
(Figure 1A). Western blot analysis of sFRP4 protein
levels determined that the normal cell line IOSE
expressed significantly higher levels of sFRP4 (p < 0.001)
compared to the cancer cells. Furthermore, the chemo-
sensitive A2780 cells also exhibited significantly higher
levels of sFRP4 (p < 0.001) compared to the chemoresis-
tant cell lines (Figure 1B). A representative image of the
Western blot is shown in Additional file 1: Figure S1.
sFRP4 expressing cells are selectively killed by Cisplatin
Analysis of MTS cell viability assays following Cisplatin
treatment demonstrated that both the IOSE and A2780
cells, which were shown to express more sFRP4, had a
significant reduction (p < 0.001) in cell viability com-
pared to untreated controls within 24 h for all three
treatment doses administered, and continued to exhibit
decreased viability for the remaining time points
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n across four cell lines. (B) sFRP4 protein expression across four cell























































Figure 2 Graphical representation of cell viability following various doses of Cisplatin treatment with time. (A) Percentage of live cells
after 24 hours treatment with 3 doses of Cisplatin (1, 5 and 10 μg). (B) Percentage of viable cells following 48 hours of Cisplatin treatment. Values
represent means for each group ± SEM (* p < 0.001 one way ANOVA and LSD).
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was shown at 48 h after treatment (Figure 2B).
Following Cisplatin treatment, only IOSE cells demon-
strated significant mitochondrial membrane depolarization
in all treatment groups within 24 h after treatment. Al-
though the chemosensitive cell line A2780 demonstrated
decreased cell viability in all three treatment groups, cell
death was detected only at the treatment dose of 10 μg/ml.
In contrast, cell death was detected in the chemoresistant
cell lines only after 48 h treatment (p < 0.001) (Figure 3),
suggesting that their lower sFRP4 levels could potentially
be one of the factors influencing the delayed response of
these cells.
IHC revealed that sFRP4 expression could not be
detected in the majority of surviving cells. Compared to
untreated controls, the percentage of IOSE cells still
expressing sFRP4 had decreased by 70% following treat-
ment with Cisplatin (10 μg/ml) for 48 h (Figure 4A, B).
Similarly, the chemosensitive cell line A2780 also
demonstrated a reduction of about 45% of its sFRP4expressing cell population following treatment. In com-
parison, the chemoresistant cell lines demonstrated a
greater percentage of live cells following treatment and
only showed a reduction of 25% in the number of cells
expressing sFRP4. Additionally, the difference in num-
bers of sFRP4 expressing cells between chemosensitive
and chemoresistant cell lines was highly significant
(p < 0.01) (Figure 4C).Over expression of sFRP4 enhanced chemosensitivity of
tumour cells
Since chemotherapy appeared to be selectively killing
sFRP4 expressing cells, we sought to test this relation-
ship further by transfecting the chemoresistant cell lines
with a plasmid expressing sFRP4 before treating them
with Cisplatin. Results showed that increasing sFRP4 ex-
pression of the chemoresistant cell lines A2780-ADR
and A2780-Cis (Additional file 2: Figure S2A) before




































Figure 3 Quantification of cell death by JC-1 analysis (red/green fluorescence ratio) with 3 doses of Cisplatin (1, 5 and 10 μg) for
48 hours. Values represent means for each group ± SEM (* p < 0.001 one way ANOVA and LSD).
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to control groups (Figure 5A and B respectively).
Down regulation of sFRP4 decreased chemosensitivity of
tumour cells
Data generated from cell viability and cell death assays
showed an inverse relationship between sFRP4 expres-
sion and the response of tumour cells to Cisplatin treat-
ment. To further investigate this correlation, the sFRP4
expression levels of the chemosensitive cell line A2780
was knocked down using siRNA. The A2780 cells trea-
ted with sFRP4-siRNA demonstrated a 40% decrease in
sFRP4 mRNA and protein expression compared to con-
trol cells (Additional file 2: Figure S2B and C). Results
showed that the control group subjected to Cisplatin
treatment exhibited a 60% reduction in cell viability
compared to untreated controls. However, the cells sub-
jected to sFRP4-siRNA treatment only exhibited a 40%
reduction in cell viability following treatment with
Cisplatin compared to control cells (Figure 6). The rela-
tive increase in cell viability of Cisplatin treated sFRP4-
siRNA cells indicates that decreasing sFRP4 in chemo-
sensitive cells caused more resistance to Cisplatin.
Differential sFRP4 expression was correlated to its
interaction with the Wnt/β-catenin signalling pathway
Western blot analysis for β-catenin protein showed that
in contrast to sFRP4, all three cell lines exhibited ele-
vated levels of β-catenin, indicating the presence of an
active Wnt pathway (Figure 7A; a representative image
of the Western blot is shown in Additional file 3: Figure
3A). Although the un-transfected chemoresistant cell
lines showed relatively high β-catenin expression, this
expression could not be detected in the sFRP4-transfected cells. Additionally, the 40% decrease of
sFRP4 expression in chemosensitive A2780 cells due to
silencing was accompanied by a corresponding increase
in β-catenin expression (Figure 7B; representative images
of the Western blots are shown in Additional file 3:
Figure S3B), confirming a functional relationship be-
tween sFRP4 and the Wnt/β-catenin signalling pathway
in this cell line.
Association of sFRP4 and stage in primary mucinous
ovarian tumours
We performed sFRP4 (Figure 8A) and β-catenin IHC on
primary mucinous ovarian cancer biopsies in tissue
microarrays (TMAs) comprising 104 primary mucinous
ovarian tumours. The TMA sections were subjectively
classified into one of four categories depending on the
percentage and intensity of the cellular sFRP4 staining:
negative, weak, moderate or strong (Figure 8A). The pri-
mary mucinous ovarian tumours were classified into
three sub-types; namely benign, borderline, and adeno-
carcinomas, and the proportion of sFRP4 and β-catenin
was quantified for each (Figure 8B). Analysis revealed
that the majority of benign and borderline tumours
exhibited sFRP4 expression, while adenocarcinomas
demonstrated a significantly reduced sFRP4 expression
compared to borderline and benign tumours (p < 0.001)
(Figure 9). An inverse trend was observed for β-catenin,
with benign tumours expressing significantly decreased
levels of β-catenin compared to the corresponding
sFRP4 expression (p < 0.001). Although borderline
tumours also showed decreased β-catenin expression
compared to sFRP4, this was not significant. In contrast
to their sFRP4 expression, adenocarcinomas expressed








































































Figure 4 (A) Light microscope images (400X) of each cell line before and after Cisplatin treatment. sFRP4 protein stained brown with DAB
and counterstained with haematoxylin for contrast (Scale bar = 50 μm). (B) Comparison of sFRP4 protein expression between untreated and
treated cells of all four cell lines. (C) Quantification of the proportion of cells stained positive for sFRP4 following Cisplatin treatment in
chemosensitive cell line A2780 vs. Chemoresistant cell lines ADR and Cis. Values represent the mean for each group ± SEM.
(* p < 0.01; ** p < 0.001 one way ANOVA and LSD).
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pression in benign and malignant mucinous tumours.
Furthermore, results also demonstrated a positive trend
between sFRP4 expression and tumour grade.
Discussion
Although the rate of cancer incidence is greater in the
breast than the ovaries, the latter has a higher relative
mortality. This is because ovarian tumours are often
diagnosed at an advanced stage. In addition, a majority
of tumours that are initially responsive to chemotherapy
eventually acquire drug-resistance to these therapeutic
agents [5,6]. Comprehending how this drug resistance
occurs is the basis for developing strategies to improve
treatment outcomes.
In this study, the five sFRP isoforms were character-
ized for the first time in a range of chemosensitive andchemoresistant human epithelial ovarian cancer cell
lines. Similar to other tumour types, several of the sFRP
isoforms were detected in ovarian cancer cells. However,
sFRP4 was the dominant isoform in all the cell lines
tested. sFRP4 was first isolated from the ovary and it is
probable that it may have specificity for this organ [20];
hence, its dominant expression could be indicative of a
specific functional role in the ovary. Similarly, sFRP4
mRNA was the only isoform to be differentially expressed
between the different cell lines. Western blots and IHC
for sFRP4 protein also confirmed that the chemoresistant
cells expressed lower levels of this protein. The differential
expression of sFRP4 seen in the chemosensitive and che-
moresistant cell lines indicated that sFRP4 could serve as
a prognostic marker for ovarian tumours.
IHC showed heterogeneous expression of sFRP4 in the






Figure 5 Effect of transfection with sFRP4 plasmid and
subsequent Cisplatin treatment for 24 hours. (A) A2780-ADR live
cell number following transfection with sFRP4 plasmid and
subsequent Cisplatin treatment for 24 hours. (B) A2780-Cis live cell
number following transfection with sFRP4 plasmid and subsequent
Cisplatin treatment for 24 hours. Values represent means for each
group ± SEM (* p < 0.001; one way ANOVA and LSD).
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which was homogenous. The chemosensitive cell line
was found to exhibit a larger sub-population of sFRP4
positive cells than the chemoresistant cells. It is known
that ovarian tumours have a heterogeneous population
of cells. Therefore it is very likely that the cells have a
differential response to chemotherapeutic treatment
[3,34]. Our results indicated that the heterogeneity of
























Figure 6 Effect of silencing of sFRP4 and subsequent Cisplatin
treatment. Graphical representation of A2780 live cell number
quantified following silencing of sFRP4 and subsequent Cisplatin
treatment for 24 hours. (* p < 0.001; one way ANOVA and LSD).the cell lines to Cisplatin, with sFRP4 expression as a
positive marker for chemosensitivity.
Furthermore, IHC of the cancerous cell lines following
treatment with Cisplatin revealed that, compared to un-
treated controls, both the chemosensitive cell line A2780
and the chemoresistant cell lines lost most of their
sFRP4 expressing cells; indicating that Cisplatin select-
ively targets sFRP4 expressing cells within the heteroge-
neous population.
Increasing the sFRP4 expression of the chemoresistant
cell lines using transfection prior to Cisplatin treatment
resulted in more cells expressing sFRP4 and, as predicted,
increased their sensitivity to treatment. In contrast, knock-
ing down sFRP4 expression of the chemosensitive A2780
cells by 40% was sufficient to confer these cells with par-
tial resistance to subsequent chemotherapeutic treatment
when compared to controls. These results are comparable
with a study by He et al., (2005), who reported that signifi-
cant down regulation of sFRP4 expression promoted cell
growth and inhibited chemotherapeutic drug-induced
apoptosis in mesothelioma cell lines [35]. Our transfection
and silencing experiments confirmed that sFRP4 appeared
to have a direct influence on the chemo-response of can-
cer cells. The data generated from this study present a
novel finding and indicate a potential avenue for future re-
search on sFRP4.
The heterogeneous expression of sFRP4 we observed
using IHC in our cell lines indicated the presence of at
least two sub-populations within ovarian cell cultures.
The chemosensitive cells had a larger population of
sFRP4 positive cells, and this correlated with their
greater sensitivity to treatment. Hypermethylation of the
sFRP4 gene has been reported in various cancers and is
associated with tumour progression and malignancy
[28,29]. We did not examine our ovarian cancer cell
lines on whether low sFRP4 expression was associated
with hypermethylation of the sFRP4 gene itself, and this
would be useful to know.
Our experiments raised some possible explanations for
acquired resistance to Cisplatin in human ovarian can-
cers. From our IHC analysis we know that Cisplatin se-
lectively targets sFRP4 expressing cells, thus continuous
treatment would gradually deplete this sub-population
of cells over time. Consequently, the resultant popula-
tion remaining would now be comprised largely of cells
that do not express sFRP4 and, hence, be more resistant
to subsequent treatment. These data suggest that loss of
sFRP4 expression is functionally associated with a more
malignant and chemoresistant phenotype, and that treat-
ment itself may select for these cells, thereby resulting in
acquired chemoresistance.
Suppression of sFRP4 in the chemosensitive cells resulted
in a corresponding increase in β-catenin expression of these



























































Figure 7 (A) β-catenin protein expression across the three cancerous cell lines. (B) Graphical representation demonstrating inverse sFRP4
and β-catenin protein expression following siRNA treatment in the chemosensitive cell line A2780. Values represent the mean for each group ±
SEM. (** = p < 0.001 one way ANOVA and LSD).
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the presence of a signalling interaction between these two
proteins in the ovarian cell lines. These findings are consist-
ent with other studies that also reported a similar inverse
relationship between these two proteins in endometrium
and breast [36,37], and suggests that sFRP4 may act as a
tumour suppressor through its interaction with the Wnt/β-
catenin signalling pathway by modulating the cellular cyto-
solic β-catenin pool.
Mucinous tumours, unlike other ovarian epithelial sub-
types, have a well characterised progression from benign to
borderline and ultimately to adenocarcinomas [38,39]. In
addition, mucinous adenocarcinomas, compared to other
subtypes, respond poorly to chemotherapy and are known
to have a poor prognosis [39]. Similar to our data, a trend
has been observed by other studies where down regulation
of sFRP4 expression was similarly associated with stage
and grade of the cancer [32,40]. These results suggest that
the progressive decline of sFRP4 expression in higher grade
disease states could be associated with both tumour pro-
gression as well as onset of chemoresistance. However, due
to our relatively low patient cohort size, this trend needs to
be assessed independently in larger patient numbers to fur-
ther validate the significance of this finding.Conclusion
Studies have shown that targeting factors that regulate
drug induced apoptosis, cell cycle arrest or inhibit angio-
genesis can influence chemosensitivity [41]. Our data are
the first to demonstrate that sFRP4 not only plays a key
role in the chemo-response of ovarian tumours but can
enable these cells to respond better to Cisplatin treat-
ment when up-regulated in chemoresistant cells. An-
other advantage of sFRP4 is that this molecule can
suppress tumourigenic growth either in the presence or
absence of the canonical Wnt/β-catenin pathway, as
demonstrated in mesothelioma cell lines by Lee et al.
(2004) and He et al. (2005) respectively [13,42].
Thus, the results from this study indicate a role for
sFRP4 as a predictive marker for ovarian cancer cell che-
mosensitivity, and suggest that targeting the sFRP4




The epithelial ovarian cancer cell lines A2780, A2780-
ADR, and A2780-Cis were obtained from the European










































Figure 8 (A) Examples of TMA scoring based on staining intensity. Light microscope images of mucinous ovarian tumour tissue (T) and
stroma (S) from the TMAs. Tissue samples expressing sFRP4 are stained brown with DAB and counterstained with haematoxylin. Images show
examples of (a) Negative (b) Weak (c) Moderate and (d) Strong staining. Scale bar = 30 μm. (B) Graphical representation of the staining intensity
quantified for sFRP4 expression and β-catenin expression respectively, following histological quantification of the tumour cores into benign, weak,
or strong. The y axis enumerates the staining intensity within each group of tumours.
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Auersperg, University of British Columbia, Vancouver,
Canada. These cell lines were cultured in RPMI 1640
supplemented with 10% foetal bovine serum, 0.5% L-
Glutamine, and 0.5% Penicillin-streptomycin. All cells were
cultured at 37°C in a humid incubator with 5% CO2.
RNA extraction and reverse transcriptase PCR
RNA from cells was extracted using Tri-Reagent (Sigma),
as per manufacturer’s instructions.
The RNA isolated was then treated with DNase (Pro-
mega) before undergoing reverse transcription by heating
to 25°C for 10 min, 55°C for 50 min and 70°C for 15 min.
After this, cDNA samples were stored at −20°C.
Quantitative real time PCR
Real time PCR was performed as previously described
[16] in a RotarGene 3000 (Corbett Research) using amaster mix comprising of SybrIQ (BioRad), sFRP pri-
mers and cDNA. The sFRP primer sequences used are
listed in Table 1. All PCR data obtained were standar-
dized against expression of GAPDH and β-Actin re-
spectively. Subsequent PCR products were sequenced
and the sequence homology of each product was then
compared with published sequence using “Blast N” on
the Pubmed “BLAST” program.
Western blotting
Whole cell lysates and Western blot analysis were per-
formed as previously described with minor modifications
[21]. Protein was extracted from cells using radioimmu-
noprecipitation (RIPA) buffer. The amount of protein
was estimated using the Bradford assay (Bradford, 1976).
The membranes were probed using anti-mouse β-catenin
primary antibody (1:1000) (Cell Signaling, Cat. no. 05–601),























Figure 9 Graphical representation of the quantified proportion
of tumours expressing sFRP4 and β-catenin based on
histological classification of mucinous tumours as benign,
borderline and adenocarcinomas. Values represent the mean for
each group ± SEM. (* p < 0.001).
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Membranes were imaged and quantitated using the Kodak
Imagestation 2000MM.
Immunohistochemistry (IHC)
Cells were grown on 22 mm × 22 mm glass cover slips
in 6-well plates in 2 ml of medium containing 100,000
cells per ml. At 24 h fresh medium containing 10 μg
Cisplatin or control medium was added and cells were
cultured for a further 48 h. The cells were fixed and
stained for expression of sFRP4 and β-catenin. The anti-

















Reverse: GGACAGAGTCTTGATGATCTC(1:100) and anti-mouse β-catenin primary antibody
(1:250). A Nikon (Tokyo, Japan) Eclipse 90i microscope
at 40 × objective and a Coolsnap ES camera (Roper
Scientific, Duluth, GA) were used for observations and
photography of the slides.
Cell treatment studies
The cells were seeded at density of 50,000 cells per ml
(5000 cells per well) onto 96-well plates in 100 μl
medium. The cells were allowed to attach for 24 h
before 1, 5, and 10 μg/ml concentrations of Cisplatin
(Oncotain, Mayne Pharma, VIC, Australia) were added
with fresh medium together with a vehicle control
(PBS). Cells were further incubated for 24, 48 or 72 h.
MTS cell viability assay
Cellular viability was assessed by a MTS assay using a Cell
Titer 96 Aqueous One solution cell viability kit (Promega,
Madison, WI) containing a tetrazolium compound 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sul-
fophenyl)-2H-tetrazolium (MTS) (yellow), which is reduced
by the mitochondria of viable cells to a purple coloured for-
mazan product. Briefly, the cells were seeded and treated.
At each time-point 20 μl of MTS reagent was added to the
cells and the optical density of the coloured product (i.e.
formation of formazan) was measured on a photometric
plate reader (Labsystems Multiskan RC) at 490 nm after in-
cubation for 3 h. The absorbance reading for each treat-
ment and time point was calculated and equated against its
corresponding control samples in order to determine the
effect of Cisplatin on the viability/survival rates of each cell
line.rature
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Quantification of cell death was determined using the
JC-1 technique [43] (Invitrogen). At the onset of cell
death, the mitochondrial membrane is rapidly depolar-
ized. When the mitochondrial membrane is polarized,
the JC-1 dye (5,50,6,60-tetrachloro-1,10,3,30-tetraethyl-
benzimidazolyl-carbocyanine iodide) aggregates and
fluoresces red. Upon depolarization, JC-1 forms a green
fluorescent monomer, so the ratio of aggregated to mono-
meric JC-1 gives a quantitative representation of the ex-
tent of mitochondrial membrane permeability. Positive
controls were conducted by the addition of 50 μM FCCP
(carbonyl cyanide p-(trifluoromethoxy) phenylhydrazone).
Cells undergoing cell death primarily demonstrate green
fluorescence while healthy cells fluoresce red/green. JC-1
cell death assays were conducted following Cisplatin treat-
ment for all three time-points (24, 48, 72 h). Plates were
analysed using a FluoStar fluorescent plate reader at 520
(green) and 590 nm (red).
Transient transfections
Cells of chemoresistant cell lines (A2780-ADR and
A2780-Cis) were plated in 96-well plates 24 hours before
transfection. Lipofectamine 2000 (Invitrogen) was used
to mediate transfection using 0.2 μg sFRP4 cDNA con-
struct in pEGFP-N1 plasmid vector (ClonTechInc)
(kindly provided by Prof Robert Friis) or empty pEGFP-
N1 vector as control as per the manufacturer’s protocol.
RNA interference
Cells of the chemosensitive cell line A2780 were plated
in 96-well plates 24 hours before silencing. RNA inter-
ference was conducted using sFRP4 siRNA and non-
silencing siRNA control (> 97% pure) purchased from
Qiagen-Xeragon (Germantown, MD). The targeted se-
quence of sFRP4 siRNA is 5-AAGTCCCGCTCATTA
CAAATT-3, corresponding to +701 to +721 of the
human sFRP4 cDNA sequence (the start codon ATG is
defined as +1). Following siRNA treatment, the level of
sFRP4 in A2780 cells was assessed by performing qPCR
and Western blots on mRNA and protein extracted from
the cells.
Tissue microarrays
Archived mucinous ovarian tumour tissue (stored as
paraffin embedded tumour blocks) were sourced from
the Western Australian Research Tissue Network at St
John of God HealthCare SJOGHC), with ethical approval
from the SJOGHC Human Research Ethics Committee.
Tissue microarrays (TMAs) were prepared as previously
described [44]. Immunohistochemical staining for sFRP4
and β-catenin were performed as described previously
[45]. The TMAs were probed using anti- β-catenin pri-
mary antibody (1:150) (Cell Signaling, Cat. no. 05–601)and anti- sFRP4 (1:100) (Upstate. Cat. No. 09–129). The
TMA sections were subjectively classified into one of
four categories depending on the percentage and inten-
sity of the cellular staining: negative, weak, moderate, or
strong. The sFRP4 and β-catenin expression of all cores
(weak, moderate, or strong) for each patient was averaged
and quantitated. Next, each tumour core was classified
based on their histological subtype (benign, borderline, or
adenocarcinoma), and the total sFRP4 and β-catenin ex-
pression for each subtype was then quantitated.
Statistical analysis
Data were analysed using one-way ANOVA and post
hoc Dunnett's test with SPSS statistics program version
17.0. Data generated from TMAs were analysed using
log rank tests to compare between groups, and chi-
squared tests to determine significance between groups.
A “p value” of less than 0.05 was considered statistically
significant.
Additional files
Additional file 1: Figure S1. A representative image of a Western blot
showing sFRP4 protein expression across the four cell lines.
Additional file 2: Figure S2. Representative images cut from Western
blots demonstrating (A) sFRP4 protein expression was increased in the
chemoresistant cell lines following transfection with sFRP4 plasmid; (B)
sFRP4 mRNA expression of chemosensitive cell line A2780 was knocked
down using siRNA; (C) sFRP4 protein expression of A2780 cells following
siRNA treatment.
Additional file 3: Figure S3. Representative images cut from Western
blots demonstrating (A) β-catenin protein expression across the three cell
lines; (B) β-catenin protein expression in chemosensitive A2780 cells
following siRNA treatment.
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